[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604696":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":47,"collaborators":25,"id":49,"slug":25,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":25,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":25,"enrollmentInfo":58,"targetDuration":25,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":25,"overallStatus":67,"whyStopped":25,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence A (RT)","EXPERIMENTAL","Period 1: Reference (AD-117A), Period 2: Test (AD-117)",[13,14],"Drug: AD-117","Drug: AD-117A",{"label":16,"type":10,"description":17,"interventionNames":18},"Sequence B (TR)","Period 1: Test (AD-117), Period 2: Reference (AD-117A)",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","AD-117","AD-117 1Tab., Per Oral",[9,16],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"AD-117A","AD-117A 1Tab., Per Oral",[9,16],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Dasom Kim","CONTACT","+82-31-891-5572","dskim@addpharma.co.kr",[37],{"facility":38,"status":25,"city":39,"state":25,"zip":25,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":25},"H Plus Yangji Hospital","Seoul","South Korea",{"type":42,"coordinates":43},"Point",[44,45],126.9784,37.566,{"lat":45,"lon":44},{"type":48,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100604696",false,"NCT07152873","A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117A","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-117 Compared to AD-117A in Healthy Adult Volunteers Under Fed State Conditions","Inclusion Criteria:\n\n* Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 in healthy volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"ALL","19 Years",{"count":59,"type":60},60,"ESTIMATED","INTERVENTIONAL",[63],"PHASE1","Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-117 in healthy subjects.",[66],"Mixed Dyslipidemia","NOT_YET_RECRUITING","2025-11-27",{"date":70,"type":71},"2025-12-04","ACTUAL",{"date":73,"type":60},"2025-12-01",{"date":75,"type":60},"2026-03",{"name":5,"class":6},1]